Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - Review

作者: Thyago José Arruda Pacheco , Victor Carlos Mello da Silva , Danielle Galdino de Souza

DOI: 10.33448/RSD-V9I12.11123

关键词:

摘要: A new coronavirus, identified in Wuhan, China, has spread globally, infecting millions of people and causing significant morbidity mortality. The pandemic state, declared by the World Health Organization on March 11, 2020, transformed world made adapt to social distance control virus. race against time search therapeutic solutions become essential, nanotechnology may be able make vaccines available record stimulate immunization individuals. Since beginning scientists companies are rapidly advancing vaccine candidates at a different rate compared other pandemics that have existed. This review briefly presents pros cons third generation vaccines, Moderna / NIAID Pfizer - BioNTech, which phase 3 tests, based lipid RNA nanoparticles. Great collaborative efforts being invested so soon population will receive doses with proven efficacy enable increased survival, since already caused many irreversible losses.

参考文章(10)
Jinjun Shi, Alexander R. Votruba, Omid C. Farokhzad, Robert Langer, Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications Nano Letters. ,vol. 10, pp. 3223- 3230 ,(2010) , 10.1021/NL102184C
Domenico Cucinotta, Maurizio Vanelli, WHO Declares COVID-19 a Pandemic. Acta bio-medica : Atenei Parmensis. ,vol. 91, pp. 157- 160 ,(2020) , 10.23750/ABM.V91I1.9397
Young Chan Kim, Barbara Dema, Arturo Reyes-Sandoval, COVID-19 vaccines: breaking record times to first-in-human trials npj Vaccines. ,vol. 5, pp. 34- 34 ,(2020) , 10.1038/S41541-020-0188-3
Lisa A Jackson, Evan J Anderson, Nadine G Rouphael, Paul C Roberts, Mamodikoe Makhene, Rhea N Coler, Michele P McCullough, James D Chappell, Mark R Denison, Laura J Stevens, Andrea J Pruijssers, Adrian McDermott, Britta Flach, Nicole A Doria-Rose, Kizzmekia S Corbett, Kaitlyn M Morabito, Sijy O’Dell, Stephen D Schmidt, Phillip A Swanson, Marcelino Padilla, John R Mascola, Kathleen M Neuzil, Hamilton Bennett, Wellington Sun, Etza Peters, Mat Makowski, Jim Albert, Kaitlyn Cross, Wendy Buchanan, Rhonda Pikaart-Tautges, Julie E Ledgerwood, Barney S Graham, John H Beigel, None, An mRNA Vaccine against SARS-CoV-2 — Preliminary Report The New England Journal of Medicine. ,vol. 383, pp. 1920- 1931 ,(2020) , 10.1056/NEJMOA2022483
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Vanessa Raabe, Ruth Bailey, Kena A Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Özlem Türeci, Kristin R Tompkins, Edward E Walsh, Robert Frenck, Ann R Falsey, Philip R Dormitzer, William C Gruber, Uğur Şahin, Kathrin U Jansen, None, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. ,vol. 586, pp. 589- 593 ,(2020) , 10.1038/S41586-020-2639-4
Lanxiang Huang, Yuan Rong, Qin Pan, Kezhen Yi, Xuan Tang, Qian Zhang, Wei Wang, Jianyuan Wu, Fubing Wang, SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies. Asian Journal of Pharmaceutical Sciences. ,vol. 16, pp. 136- 146 ,(2021) , 10.1016/J.AJPS.2020.08.001
Estefânia V. R. Campos, Anderson E. S. Pereira, Jhones Luiz de Oliveira, Lucas Bragança Carvalho, Mariana Guilger-Casagrande, Renata de Lima, Leonardo Fernandes Fraceto, How can nanotechnology help to combat COVID-19? Opportunities and urgent need. Journal of Nanobiotechnology. ,vol. 18, pp. 1- 23 ,(2020) , 10.1186/S12951-020-00685-4
Victor Carlos Mello da Silva, Danielle Galdino De Souza, Raquel Santos Faria, Franciéle de Matos da Silva, Thyago José Arruda Pacheco, Coronavirus disease 2019 (COVID-19): Updated evidence of comparative overview, diagnosis and treatments: REVISTA CEREUS. ,vol. 12, pp. 228- 243 ,(2020)